Skip to content

The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02930564
Enrollment
10
Registered
2016-10-12
Start date
2017-01-31
Completion date
2022-05-29
Last updated
2022-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Brief summary

The Challenge study is a prospective, open label, pilot trial in patients in deep remission on dietary maintenance therapy. The purpose of this study is to determine whether they can consume some of the products that were eliminated from their diet, named the Crohn's Disease Exclusion Diet (CDED), and to evaluate if low dose exposure is harmful.

Detailed description

The investigators have previously hypothesized that Crohn's disease may occur via a sequence of events involving dysbiosis and genetically determined or environmentally acquired defects in innate immunity, and have further hypothesized that the mechanism of EEN for induction of remission acts by reducing exposure to dietary components that may cause an acquired bacterial clearance defect or generate dysbiosis. Based on this premise, the investigators developed a new exclusion diet. This diet, named the Crohn's Disease Exclusion Diet (CDED) reduces exposure to all the components identified in rodent models as well as two components that are highly suspect but have not been investigated in models. This diet was evaluated for induction of remission through week 12 and succeeded in inducing remission in 70% of 47 selected patients. The investigators have now progressed to three randomized controlled trials to evaluate the diet in different populations with different disease severity, and the results from the first RCT demonstrate a high remission rate in the CDED arm. However , to date the investigators have used the same diet for all patients. The investigators are now encountering patients on the diet in deep remission, but the investigators do not know if they can consume some of the products ( such as milk fat and gluten) that were eliminated. The investigators therefore are starting to challenge our patients in deep remission with low dose exposure to evaluate if low dose exposure is harmful. The investigators wish to document this and obtain stool samples for calprotetctin and microbiome to investigate these patients at a microbiological level as well.

Interventions

OTHERCDED + milk fat and gluten

CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)

Sponsors

Wolfson Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to 20 Years
Healthy volunteers
No

Inclusion criteria

1. Established diagnosis of Crohn's disease. 2. Patients in sustained remission with PCDAI 0 \> 6 months 3. Ages 8-20 4. Normal CRP (CRP\<0.5), normal Calprotectin (\<100) 5. Patients with uncomplicated disease 6. Signed informed consent

Exclusion criteria

1. Patients with active disease (PCDAI \>10) 2. Pregnancy 3. Patients with complicated disease (B2, B3) 4. Patients with recent onset use of an immunomodulator \<12 weeks, or dose change in past 12 weeks. 5. Patients with current use of biologics. 6. Elevated CRP or Calprotetcin\>100 at screening.

Design outcomes

Primary

MeasureTime frame
number of patients with calprotetctin elevationday 14 or 21

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026